Paclitaxel Treatment Options

A collection of 2017 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Home

All Treatments

Paclitaxel

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT03639246

Completed

This is a Phase 1b/2 study of AVB-S6-500 in combination with pegylated liposomal doxorubicin (PLD) or paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. The phase 1b portion of the study is open label and patients will receive either AVB-S6-500+PLD or AVB-S6-500+ Pac. The Phase 2 portion of the study is randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with PLD or Pac versus placebo plus PLD or Pac.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/10/2023

Locations: Arizona Oncology, Phoenix, Arizona +15 locations

Conditions: Ovarian Cancer

Learn More ›

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02930902

Completed

This phase Ib trial studies the side effects and best way to give pembrolizumab and paricalcitol with or without chemotherapy in patients with pancreatic cancer that can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help carry tumor-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/07/2023

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7

Learn More ›

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

NCT03321188

Unknown

This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days of HIPEC and cytoreduction. All patients will receive cytoreductive surgery followed by a one-time closed HIPEC with cisplatin at 41-43 degrees Celsius for 90 minutes in the operating room. This is followed by 6 cycles of intravenous carboplatin and paclitaxel on an outpa... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/03/2023

Locations: The University of Kansas Cancer Center, Kansas City, Kansas

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer

Learn More ›

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

NCT02041533

Completed

The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2023

Locations: Southern Cancer Center, Inc., Mobile, Alabama +140 locations

Southern Cancer Center, Inc., Mobile, Alabama

Banner MD Anderson Cancer Center, Gilbert, Arizona

Local Institution - 0034, Tucson, Arizona

Local Institution - 0016, Stanford, California

University Of Colorado Hosp, Aurora, Colorado

Local Institution - 0020, New Haven, Connecticut

Local Institution - 0030, Miami, Florida

Local Institution - 0033, Ocala, Florida

H. Lee Moffitt Cancer Center, Tampa, Florida

Local Institution - 0010, Atlanta, Georgia

Northwest Georgia Oncology Center, P.C., Marietta, Georgia

Local Institution - 0037, Chicago, Illinois

Local Institution - 0014, Lexington, Kentucky

Crescent City Research Consortium, LLC, Marrero, Louisiana

Local Institution - 0024, Baltimore, Maryland

Local Institution - 0036, Boston, Massachusetts

Local Institution - 0070, Boston, Massachusetts

Roswell Park Cancer Institute, Buffalo, New York

Local Institution - 0009, New York, New York

Local Institution - 0005, New York, New York

University Of North Carolina At Chapel Hill, Chapel Hill, North Carolina

Local Institution - 0003, Durham, North Carolina

Local Institution - 0012, Cleveland, Ohio

Local Institution - 0027, Columbus, Ohio

Oregon Health & Science University, Portland, Oregon

Local Institution - 0007, Allentown, Pennsylvania

Local Institution - 0054, Philadelphia, Pennsylvania

Local Institution - 0002, Philadelphia, Pennsylvania

Local Institution - 0018, Pittsburgh, Pennsylvania

Local Institution - 0011, Charleston, South Carolina

Local Institution - 0038, Greenville, South Carolina

Local Institution - 0008, Nashville, Tennessee

Local Institution - 0006, Dallas, Texas

Local Institution - 0023, Houston, Texas

Cancer Centers of South Texas, San Antonio, Texas

Local Institution - 0029, Yakima, Washington

Local Institution - 0051, Berazategui, Buenos Aires

Local Institution - 0049, Capital Federal, Buenos Aires

Local Institution - 0052, Ciudad Autonoma De Buenos Aire, Buenos Aires

Local Institution - 0048, Cordoba, Not set

Local Institution - 0050, Cordoba, Not set

Local Institution - 0090, Camperdown, New South Wales

Local Institution - 0091, Brisbane, Queensland

Local Institution - 0071, Elizabeth Vale, South Australia

Local Institution - 0072, Fitzroy, Victoria

Local Institution - 0104, Heidelberg, Victoria

Local Institution - 0088, Wels, Not set

Local Institution - 0087, Wien, Not set

Local Institution - 0044, Brussels, Not set

Local Institution - 0055, Edegem, Not set

Local Institution - 0056, Gent, Not set

Local Institution - 0062, Leuven, Not set

Local Institution - 0134, Ijui, Rio Grande Do Sul

Local Institution - 0133, Porto Alegre, Rio Grande Do Sul

Local Institution - 0135, Barretos, Sao Paulo

Local Institution - 0086, Calgary, Alberta

Local Institution - 0115, Hamilton, Ontario

Local Institution - 0113, Toronto, Ontario

Local Institution - 0110, Montreal, Quebec

Local Institution - 0109, Rimouski, Quebec

Local Institution - 0059, Olomouc, Not set

Local Institution - 0061, Ostrava - Poruba, Not set

Local Institution - 0058, Praha 8, Not set

Local Institution - 0060, Usti nad Labem, Not set

Local Institution - 0120, Helsinki, Not set

Local Institution - 0119, Tampere, Not set

Local Institution - 0118, Vaasa, Not set

Local Institution - 0123, Caen, Not set

Local Institution - 0105, Lille, Not set

Local Institution - 0102, Marseille Cedex 20, Not set

Local Institution - 0167, Pontoise Cedex, Not set

Local Institution - 0100, Rennes Cedex 9, Not set

Local Institution - 0140, Strasbourg, Not set

Local Institution - 0074, Bamberg, Not set

Local Institution - 0065, Grosshansdorf, Not set

Local Institution - 0064, Heidelberg, Not set

Local Institution - 0063, Koeln, Not set

Local Institution - 0066, Stuttgart, Not set

Local Institution - 0092, Wiesbaden, Not set

Local Institution - 0073, Heraklion, Creta

Local Institution - 0075, Athens, Not set

Local Institution - 0126, Budapest, Not set

Local Institution - 0116, Debrecen, Not set

Local Institution - 0094, Matrahaza, Not set

Local Institution - 0084, Avellino, Not set

Local Institution - 0079, Livorno, Not set

Local Institution - 0143, Milano, Not set

Local Institution - 0142, Napoli, Not set

Local Institution - 0083, Perugia, Not set

Local Institution - 0082, Terni, Not set

Local Institution - 0161, Nagoya-shi, Aichi

Local Institution - 0146, Nagoya, Aichi

Local Institution - 0148, Matsuyama-shi, Ehime

Local Institution - 0153, Kobe City, Hyogo

Local Institution - 0144, Natori-shi, Miyagi

Local Institution - 0151, Niigata-shi, Niigata

Local Institution - 0166, Habikino-shi, Osaka

Local Institution - 0147, Miyakojima-ku, Osaka

Local Institution - 0145, Osaka-sayama, Osaka

Local Institution - 0152, Sakai, Osaka

Local Institution - 0150, Kitaadachi-gun, Saitama

Local Institution - 0149, Sunto-gun, Shizuoka

Local Institution - 0154, Chuo-ku, Tokyo

Local Institution - 0159, Akashi, Hyogo, Not set

Local Institution - 0162, Ota, Gunma, Not set

Local Institution - 0165, Sapporo, Hokkaido, Not set

Local Institution - 0160, Tokyo, Not set

Local Institution - 0158, Wakayama, Not set

Local Institution - 0155, Gangnam-gu, Not set

Local Institution - 0164, Seoul, Not set

Local Institution - 0163, Seoul, Not set

Local Institution - 0117, Mexico, Distrito Federal

Local Institution - 0122, Guadalajara, Jalisco

Local Institution - 0124, Merida, Yucatan

Local Institution - 0045, Amsterdam, Not set

Local Institution - 0057, Groningen, Not set

Local Institution - 0046, Rotterdam, Not set

Local Institution - 0114, Bydgoszcz, Not set

Local Institution - 0131, Krakow, Not set

Local Institution - 0139, Lodz, Not set

Local Institution - 0089, Warszawa, Not set

Local Institution - 0093, Wodzislaw Slaski, Not set

Local Institution - 0068, Cluj Napoca, Not set

Local Institution - 0067, Cluj-napoca, Not set

Local Institution - 0069, Ploiesti, Not set

Local Institution - 0040, Barcelona, Not set

Local Institution - 0041, Las Palmas De Gran Canaria, Not set

Local Institution - 0047, Madrid, Not set

Local Institution - 0042, Malaga, Not set

Local Institution - 0039, Sevilla, Not set

Local Institution - 0043, Valencia, Not set

Local Institution - 0127, Stockholm, Not set

Local Institution - 0125, Uppsala, Not set

Local Institution - 0076, Chur, Not set

Local Institution - 0077, Lausanne, Not set

Local Institution - 0078, Zuerich, Not set

Local Institution - 0157, Taipei, Not set

Local Institution - 0130, Kayseri, Not set

Local Institution - 0098, London, Greater London

Local Institution - 0097, Manchester, Greater Manchester

Local Institution - 0053, Leeds, Yorkshire

Conditions: Stage IV or Recurrent Non-Small Cell Lung Cancer

Learn More ›

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

NCT02210559

Completed

This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/02/2023

Locations: HonorHealth Research Institute, Scottsdale, Arizona +7 locations

Conditions: Pancreatic Cancer (Unresectable)

Learn More ›

PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer

NCT02067416

Withdrawn

Study of the assay, Mammostrat®. to verify its utility as a predictor or outcome tool to determine whom would benefit from chemotherapy prior to surgery. Also could be used as a clinical marker to identify patients with breast cancer who do not benefit from some preoperative chemotherapies.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/31/2023

Locations: Houston Methodist Hospital, Houston, Texas

Conditions: Breast Cancer

Learn More ›

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

NCT05453825

Unknown

This is a study of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced cancer. Patients will be enrolled into one of the following cancer cohorts: * Cohort A: CRC * Cohort B: Gastric and GEJ cancer * Cohort C: TNBC * Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/30/2023

Locations: Genesis Cancer Center, Hot Springs, Arkansas +7 locations

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer

Learn More ›

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

NCT01446016

Completed

The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed anthracycline based therapy. The investigators want to see the response of breast cancer cell when treated with Chloroquine used in combination with chemotherapy. Chemotherapy is an anti-cancer drug that is given through your vein. The chemotherapy used in this study is either Ta... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/19/2023

Locations: Houston Methodist Hospital Cancer Center, Houston, Texas +2 locations

Conditions: Breast Neoplasms, Breast Cancer

Learn More ›

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer

NCT01647828

Completed

The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 in combination with nab-paclitaxel and gemcitabine followed by a Phase 2, multicenter, randomized, placebo-controlled portion to evaluate the efficacy and safety of OMP-59R5 in combination with nab-paclitaxel and gemcitabine in subjects with previously untreated stage IV pancreatic cancer.

Gender:

ALL

Ages:

Between 18 years and 90 years

Trial Updated:

01/19/2023

Locations: Western Regional Medical Center, Inc., Goodyear, Arizona +25 locations

Western Regional Medical Center, Inc., Goodyear, Arizona

CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center, Bakersfield, California

St Jude Heritage Healthcare Virginia K. Crosson Cancer Center, Fullerton, California

Pacific Shores Medical Group, Long Beach, California

Ronald Reagan UCLA Medical Center, Drug Information Center, Department of Pharmaceutical Services, Los Angeles, California

Torrance Health Association Dba Torrance Memorial Physician Network/Cancer Care Associates, Redondo Beach, California

Rocky Mountain Cancer Centers, Denver, Colorado

Orlando Health, Inc., Orlando, Florida

Northside Hospital, Inc. - GCS/Almex, Atlanta, Georgia

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Michigan Health System, Ann Arbor, Michigan

Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota

Washington University School of Medicine, Saint Louis, Missouri

Comprehensive Cancer Centers ofNevada, Las Vegas, Nevada

Memorial Sloan-Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

Oncology Hematology Care, Inc., Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma

Bend Memorial Clinic, Bend, Oregon

Greenville Health System, Clinical Research Unit, Institute for Translational Oncology Research, Greenville, South Carolina

Sarah Cannon Research Institute, Nashville, Tennessee

South Texas Accelerated Research Thereapeutics, LLC (START), San Antonio, Texas

Virginia Mason Medical Center, Seattle, Washington

University of Wiscons in Hospi tal and Clinics, Madison, Wisconsin

Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Stage IV Pancreatic Cancer

Learn More ›

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

NCT03301350

Completed

This is a phase II single-arm, open-label, prospective study to evaluate the efficacy of the low dose weekly Carboplatin/Paclitaxel followed by dose-dense Doxorubicin/Cyclophosphamide in subjects with triple-negative breast cancer in neoadjuvant settings.

Gender:

ALL

Ages:

Between 18 years and 74 years

Trial Updated:

01/09/2023

Locations: Swedish American Hospital, Rockford, Illinois +5 locations

Conditions: Breast Cancer, Triple Negative Breast Cancer

Learn More ›

A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)

NCT03398655

Completed

The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant Ovarian Cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

01/08/2023

Locations: UAB Division of GYN Oncology, Birmingham, Alabama +93 locations

UAB Division of GYN Oncology, Birmingham, Alabama

Western Regional Medical Center, Goodyear, Arizona

Arizona Oncology Associates, PC - HAL - USO, Phoenix, Arizona

Arizona Oncology Associates, PC - HAL - USO, Tempe, Arizona

University of Arizona Cancer Center, Tucson, Arizona

UCLA-JCCC-Women's Health Clinical Research Unit, Los Angeles, California

The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California

University of California, Irvine Medical Center/Chao Family Comprehensive Cancer Center, Orange, California

University of California - San Francisco, San Francisco, California

Sansum Clinic - USO, Santa Barbara, California

Olive View UCLA Medical Center, Sylmar, California

Hartford HealthCare Cancer Institute at the Hospital of Central Ct, Hartford, Connecticut

Hartford Healthcare, Hartford, Connecticut

UF Health, Gainesville, Florida

University of Miami, Miami, Florida

Emory University, Atlanta, Georgia

Rush University Medical Center, Chicago, Illinois

Carle Cancer Center, Urbana, Illinois

Midwestern Regional Medical Center, Inc, Zion, Illinois

Parkview Cancer Institute, Fort Wayne, Indiana

Indiana University School of Medicine, Indianapolis, Indiana

St. Vincent Gynecologic Oncology, Indianapolis, Indiana

University of Kansas Cancer Center, Westwood, Kansas

University of Kentucky, Lexington, Kentucky

Ochsner Clinic Foundation, New Orleans, Louisiana

University of Maryland, Baltimore, Maryland

Holy Cross Hospital, Silver Spring, Maryland

Massachusetts General Hospital, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Karmanos Cancer Institute, Detroit, Michigan

Henry Ford Health Hospital, Detroit, Michigan

Dartmouth- Hitchcock Medical Center, Lebanon, New Hampshire

Atlantic Health System/Morristown Medical Center, Morristown, New Jersey

Rutgers New Jersey Medical School, Newark, New Jersey

New Mexico Cancer Care Alliance, Albuquerque, New Mexico

Women's Cancer Care Associates, LLC, Albany, New York

Westchester Medical Center, Hawthorne, New York

Northwell Health Cancer Institute, Lake Success, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

Health Quest Medical Practice, Division of Gynecology/Oncology Gyno Dyson Cancer Center Vassar Brothers Medical Center, Poughkeepsie, New York

SUNY Upstate Medical University, Syracuse, New York

UNC Chapel Hill, Chapel Hill, North Carolina

Duke University-Duke Cancer Institute, Durham, North Carolina

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

Sanford Medical Center, Fargo, North Dakota

University of Cincinnati, Cincinnati, Ohio

Womens Cancer Center/Kettering Cancer Care, Kettering, Ohio

University of Oklahoma Health Sciences Center-Stephenson Cancer Center, Oklahoma City, Oklahoma

Willamette Valley Cancer Institute and Research Center, Eugene, Oregon

St. Luke's University Health Network, Bethlehem, Pennsylvania

Penn State Hershey Medical Center, Hershey, Pennsylvania

The University of Pennsylvania, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

West Penn Hospital, Pittsburgh, Pennsylvania

GHS Cancer Institute, Greenville, South Carolina

Sanford Clinical Research, Sioux Falls, South Dakota

Texas Oncology, Austin Central - USO, Austin, Texas

Memorial Hermann, Houston, Texas

UT Health, San Antonio, Texas

Universtiy of Vermont, Burlington, Vermont

MultiCare Institute for Research & Innovation, Tacoma, Washington

University of Wisconsin, Madison, Wisconsin

Marshfield Clinic Cancer Care & Research Center, Marshfield, Wisconsin

Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin

Rambam Medical Center, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Shaare Tzedek Medical Center, Jerusalem, Not set

Rabin Medical Center, Petach Tikva, Not set

Chaim Sheba Medical Center, Ramat Gan, Not set

Kaplan Medical Center, Department of Oncology, Rehovot, Not set

Aichi Cancer Center, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Ehime University Hospital, Tōon, Ehime

Kurume University Hospital, Kurume, Fukuoka

Sapporo Medical University Hospital, Sapporo, Hokkaido

Iwate Medical University Hospital, Shiwa-gun, Iwate

Tohoku University Hospital, Sendai, Myagi

National Defense Medical College Hospital, Tokorozawa, Saitama

National Cancer Center Hospital, Chuo-ku, Tokyo

Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto, Tokyo

Niigata Cancer Center Hospital, Niigata, Not set

Hokkaido University Hospital, Sapporo, Not set

Centrum Badan Klinicznych Jagiellonskiego Centrum Innowacji, Kraków, Not set

Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Olsztyn, Not set

MedPolonia Sp. z o.o., Poznań, Not set

Parc Taulí Hospital Universitari Edifici Santa Fe, Planta 0, Sala de recerca 3, Barcelona, Not set

Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona, Not set

Hospital Universitario de Donostia Edificio Onkologikoa- Planta baja, Sala de Ensayos Clinicos, Donostia, Not set

Hospital Gregorio Marañon Módulo prefabricado Oncología, Planta Baja, Madrid, Not set

MD Anderson Cancer Center Madrid Unidad de ensayos Clinicos, Madrid, Not set

Hospital Universitario Clínico San Carlos., Madrid, Not set

Hospital Universitario Virgen del Rocío Servicio Oncología Médica. Ensayos Clínicos. Edificio CDCA, Sevilla, Not set

Instituto Valenciano de Oncología Médica (IVO, Valencia, Not set

Consorcio Hospitalario General Universitario de Valencia Servicio de Oncología Médica - Unidad de Investigación, Valencia, Not set

Conditions: Recurrent Platinum Resistant Ovarian Cancer

Learn More ›

Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer

NCT02581982

Completed

This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/06/2023

Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina

Conditions: Transitional Cell Carcinoma

Learn More ›

Browse by State

Paclitaxel treatment options in Alabama

Paclitaxel treatment options in Alaska

Paclitaxel treatment options in Arizona

Paclitaxel treatment options in Arkansas

Paclitaxel treatment options in California

Paclitaxel treatment options in Colorado

Paclitaxel treatment options in Connecticut

Paclitaxel treatment options in Delaware

Paclitaxel treatment options in District of Columbia

Paclitaxel treatment options in Florida

Paclitaxel treatment options in Georgia

Paclitaxel treatment options in Hawaii

Paclitaxel treatment options in Idaho

Paclitaxel treatment options in Illinois

Paclitaxel treatment options in Indiana

Paclitaxel treatment options in Iowa

Paclitaxel treatment options in Kansas

Paclitaxel treatment options in Kentucky

Paclitaxel treatment options in Louisiana

Paclitaxel treatment options in Maine

Paclitaxel treatment options in Montana

Paclitaxel treatment options in Nebraska

Paclitaxel treatment options in Nevada

Paclitaxel treatment options in New Hampshire

Paclitaxel treatment options in New Jersey

Paclitaxel treatment options in New Mexico

Paclitaxel treatment options in New York

Paclitaxel treatment options in North Carolina

Paclitaxel treatment options in North Dakota

Paclitaxel treatment options in Ohio

Paclitaxel treatment options in Oklahoma

Paclitaxel treatment options in Oregon

Paclitaxel treatment options in Maryland

Paclitaxel treatment options in Massachusetts

Paclitaxel treatment options in Michigan

Paclitaxel treatment options in Minnesota

Paclitaxel treatment options in Mississippi

Paclitaxel treatment options in Missouri

Paclitaxel treatment options in Pennsylvania

Paclitaxel treatment options in Rhode Island

Paclitaxel treatment options in South Carolina

Paclitaxel treatment options in South Dakota

Paclitaxel treatment options in Tennessee

Paclitaxel treatment options in Texas

Paclitaxel treatment options in Utah

Paclitaxel treatment options in Vermont

Paclitaxel treatment options in Virginia

Paclitaxel treatment options in Washington

Paclitaxel treatment options in West Virginia

Paclitaxel treatment options in Wisconsin

Paclitaxel treatment options in Wyoming